"Blast Crisis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.
| Descriptor ID |
D001752
|
| MeSH Number(s) |
C04.557.337.539.250.100 C04.697.098.500.110 C15.378.190.636.370.100 C23.550.727.098.500.110
|
| Concept/Terms |
Blast Crisis- Blast Crisis
- Blast Crises
- Crises, Blast
- Crisis, Blast
- Blast Phase
- Blast Phases
- Phase, Blast
- Phases, Blast
|
Below are MeSH descriptors whose meaning is more general than "Blast Crisis".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Leukemia [C04.557.337]
- Leukemia, Myeloid [C04.557.337.539]
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C04.557.337.539.250]
- Blast Crisis [C04.557.337.539.250.100]
- Neoplastic Processes [C04.697]
- Carcinogenesis [C04.697.098]
- Cell Transformation, Neoplastic [C04.697.098.500]
- Blast Crisis [C04.697.098.500.110]
- Hemic and Lymphatic Diseases [C15]
- Hematologic Diseases [C15.378]
- Bone Marrow Diseases [C15.378.190]
- Myeloproliferative Disorders [C15.378.190.636]
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C15.378.190.636.370]
- Blast Crisis [C15.378.190.636.370.100]
- Pathological Conditions, Signs and Symptoms [C23]
- Pathologic Processes [C23.550]
- Neoplastic Processes [C23.550.727]
- Carcinogenesis [C23.550.727.098]
- Cell Transformation, Neoplastic [C23.550.727.098.500]
- Blast Crisis [C23.550.727.098.500.110]
Below are MeSH descriptors whose meaning is more specific than "Blast Crisis".
This graph shows the total number of publications written about "Blast Crisis" by people in this website by year, and whether "Blast Crisis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 4 | 6 |
| 1995 | 1 | 3 | 4 |
| 1996 | 2 | 1 | 3 |
| 1997 | 2 | 1 | 3 |
| 1998 | 0 | 2 | 2 |
| 1999 | 5 | 2 | 7 |
| 2000 | 0 | 2 | 2 |
| 2001 | 2 | 2 | 4 |
| 2002 | 3 | 5 | 8 |
| 2003 | 2 | 8 | 10 |
| 2004 | 3 | 3 | 6 |
| 2005 | 4 | 3 | 7 |
| 2006 | 3 | 4 | 7 |
| 2007 | 6 | 2 | 8 |
| 2008 | 3 | 3 | 6 |
| 2009 | 6 | 3 | 9 |
| 2010 | 0 | 8 | 8 |
| 2011 | 4 | 3 | 7 |
| 2012 | 3 | 2 | 5 |
| 2013 | 2 | 3 | 5 |
| 2014 | 0 | 1 | 1 |
| 2015 | 5 | 2 | 7 |
| 2016 | 7 | 3 | 10 |
| 2017 | 7 | 2 | 9 |
| 2018 | 3 | 3 | 6 |
| 2019 | 2 | 1 | 3 |
| 2020 | 4 | 7 | 11 |
| 2021 | 7 | 1 | 8 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Blast Crisis" by people in Profiles.
-
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia. Cell Rep Med. 2024 Jun 18; 5(6):101585.
-
An Update on the Management of Advanced Phase Chronic Myeloid Leukemia. Curr Hematol Malig Rep. 2023 12; 18(6):234-242.
-
Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring. Leuk Lymphoma. 2023 03; 64(3):746-749.
-
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023 Jan; 10(1):e24-e34.
-
Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia. 2023 01; 37(1):5-17.
-
Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood Cancer J. 2022 10 28; 12(10):144.
-
Time to blur the blast boundaries. Cancer. 2022 04 15; 128(8):1568-1570.
-
Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. Int Rev Cell Mol Biol. 2022; 366:83-124.
-
Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol. 2021 06 15; 14(1):94.
-
From the archives of MD Anderson Cancer Center: Concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia. Ann Diagn Pathol. 2021 Aug; 53:151767.